News

2022 update of the Marie Sklodowska-Curie Actions 2021-2022 work programme – overview of changes

Published on | 3 years ago

Programmes
MSCA

The amended version of the Marie Skłodowska-Curie Actions 2021-2022 Work Programme has been published on 10 May. The updated version entails modifications to administrative requirements of the different MSCA funding schemes and an introduction of a new fellowship scheme.

  • Staff Exchanges:
    • Introduction of obligation of full-time secondments. Secondments between non-associated third countries are not eligible.
    • Clarification on the definition of interdisciplinarity.
  • Postdoctoral Fellowships:
    • Clarification on secondments in European Postdoctoral Fellowships (on duration) and Global Postdoctoral Fellowships (on location at start of the action).
    • Clarification on the evaluation of placements in the non-academic sector.
  • Doctoral Networks:
    • Steering board is now called supervisory board and reference is made to the MSCA Guidelines for supervision.
    • This rule no longer applies for Industrial Doctorates and Joint Doctorates: “Secondments are eligible for up to one third of the actual months spent implementing the research training activities under the action.”
  • Cofund: introduction of the obligation to add a Letter of Commitment from the implementing partner included in the proposal.
  • Clarification on the request and granting procedure for the Special Needs Allowance (up to 60.000/researcher or staff member) for MSCA grants funded under Horizon 2020.
  • Introduction of a new fellowship scheme “MSCA4Ukraine” (€25 million from 2022 budget) for displaced doctoral and postdoctoral researchers from Ukraine for temporary continuation of their careers in EU member states and Horizon Europe associated countries. This is a grant to an identified beneficiary thus not an open call for proposals.

myOverview - sign up for personalised information

We offer news and event updates, covering all domains and topics of Horizon Europe, Digital Europe & EDF (and occasionally, for ongoing projects, Horizon 2020).

Stay informed about what matters to you. By signing up, you can opt in for e-mail notifications and get access to a personalised dashboard that groups all news updates and event announcements in your domain(s).

Only for stakeholders located in Flanders

Latest News

1813 articles available search in articles 

Testimonial

Methylomic – Hope & Improved outcomes for Crohn’s disease patients across Europe

The METHYLOMIC project, ‘targeting hope for personalised medicine in immune-mediated inflammatory diseases’ obtained funding from Horizon Europe’s Health Cluster. The project aims to personalise treatment allocation and enhance the effectiveness of medications for chronic immune-mediated diseases such as Crohn’s disease, rheumatoid arthritis, and psoriasis. BIRD, the Belgian inflammatory bowel disease research and development group, is a partner in the project and is involved in the OmiCrohn trial, a prospective randomised clinical trial for individualised therapy in Crohn’s disease patients. With BIRD’s active role in this trial, the project is set to deliver predictive, biomarker-based therapies that bring renewed hope for Crohn’s disease patients across Europe.